论文部分内容阅读
人附睾分泌蛋白4(HE4)是近年发现的新妇科肿瘤标记物,其在正常子宫内膜及卵巢中低表达的特性使其在妇科恶性肿瘤中的诊断具有独特的价值。研究表明,HE4在卵巢癌的早期诊断、鉴别诊断等方面已显示出一定的优越性,其在评价卵巢癌的预后以及早期监测复发上可能优于糖类抗原125(CA125)。HE4对子宫内膜癌的诊断也有研究报道。HE4作为一种新肿瘤标记物与CA125联用,对卵巢癌、子宫内膜癌等妇科肿瘤的诊断、鉴别诊断、风险预测均有很好的临床价值。HE4在子宫肌瘤等良性妇科疾病的诊断及鉴别诊断中也具有一定的临床价值。
Human epididymal secreting protein 4 (HE4) is a new gynecological tumor marker discovered in recent years. Its low expression in normal endometrium and ovary has unique value in the diagnosis of gynecologic malignancies. Studies have shown that HE4 has shown some advantages in the early diagnosis and differential diagnosis of ovarian cancer. HE4 may be superior to carbohydrate antigen 125 (CA125) in evaluating the prognosis of ovarian cancer and early monitoring of recurrence. HE4 on the diagnosis of endometrial cancer have also been reported. HE4 as a new tumor marker combined with CA125 has good clinical value in the diagnosis, differential diagnosis and risk prediction of gynecological tumors such as ovarian cancer and endometrial cancer. HE4 in the diagnosis of uterine fibroids and other benign gynecological diseases and differential diagnosis also has some clinical value.